MangoGen Pharma is a privately-owned bio-engineering company with a mission to develop novel gene-delivering medical devices that improve human health. MangoGen, located in Montreal Quebec, Canada, and owns a novel patented platform technology that utilizes encapsulated genetically modified baculoviruses coated on to medical devices. On device deployment, the virus enters the local cells, delivers the human gene, and an active protein is expressed. MangoGen’s focus is a product pipeline that includes the development of the next generation of stents – a gene-delivering coronary stent, as well as a gene-delivering film-dressing to promote and accelerate wound healing (e.g. for diabetic foot ulcers), gene-delivering sutures and gene-delivering creams to prevent scar tissue formation.